» Articles » PMID: 11947912

Reduced Expression of Endothelial Cell Markers After 1 Year Treatment with Simvastatin and Atorvastatin in Patients with Coronary Heart Disease

Overview
Journal Atherosclerosis
Publisher Elsevier
Date 2002 Apr 12
PMID 11947912
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

The study was aimed at investigating the effects, after treatment for 1 year, of two different statins on the levels of circulating biochemical markers of endothelial function in patients with established coronary heart disease, with the hypothesis that statins might reduce these levels. Twenty-eight patients were randomized to treatment with atorvastatin and 30 to simvastatin for 1 year. The starting dose in both groups was 20 mg/day. Soluble forms of P-selectin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) were determined to assess inflammatory activity of the endothelium, and tissue plasminogen activator antigen (tPAag), von Willebrand factor and thrombomodulin for evaluation of the haemostatic function. In the total study population there were significantly reduced levels after 1 year treatment in ICAM-1 (P<0.001), E-selectin (P=0.022) and P-selectin (P<0.001), whereas a significant increase was observed in VCAM-1 (P=0.003). Almost the same pattern was seen within both groups although the increase in VCAM-1 was only seen in the simvastatin group (P=0.017). An overall reduction in tPAag was further observed (P=0.048). The reduction in proinflammatory and to some extent haemostatic markers of endothelial function after 1 year treatment with either simvastatin or atorvastatin may be indicative of a less activated state of the endothelium which possibly may contribute to modulation of the progression of atherosclerosis.

Citing Articles

Association of Endothelial Cell Activation with Acute Kidney Injury during Coronary Angiography and the Influence of Recombinant Human C1 Inhibitor-A Secondary Analysis of a Randomized, Placebo-Controlled, Double-Blind Trial.

Moser S, Araschmid L, Panagiotou A, Bonati L, Breidthardt T, Fahrni G Biomedicines. 2024; 12(9).

PMID: 39335470 PMC: 11428207. DOI: 10.3390/biomedicines12091956.


Statins Effects on Blood Clotting: A Review.

Siniscalchi C, Basaglia M, Riva M, Meschi M, Meschi T, Castaldo G Cells. 2023; 12(23).

PMID: 38067146 PMC: 10706238. DOI: 10.3390/cells12232719.


Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study.

Liu Z, Wang Q, Li N, Xu C, Li Y, Zhou J Front Public Health. 2023; 10:1082327.

PMID: 36699920 PMC: 9868303. DOI: 10.3389/fpubh.2022.1082327.


Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome.

Mensink F, Los J, Ten Cate T, Oemrawsingh R, Brouwer M, El Messaoudi S Front Cardiovasc Med. 2022; 9:1061346.

PMID: 36568547 PMC: 9772027. DOI: 10.3389/fcvm.2022.1061346.


Systematic Review and Meta-Analysis of the Effect of Statins on Circulating E-Selectin, L-Selectin, and P-Selectin.

Zinellu A, Mangoni A Biomedicines. 2021; 9(11).

PMID: 34829936 PMC: 8615864. DOI: 10.3390/biomedicines9111707.